2018 / 04

Next Paper
DOI: 10.24075/brsmu.2018.051

ORIGINAL RESEARCH

Parameters of vancomycin pharmacokinetics in postoperative patients with renal dysfunction: comparing the results of a pharmacokinetic study and mathematical modeling

Ramenskaya GV1, Shokhin IE1,3, Lukina MV2, Andrushishina TB2, Chukina MA2, Tsarev IL2, Vartanova OA2, Morozova TE2
About authors

1 Department of Pharmaceutical and Toxicological Chemistry, Institute of Pharmacy,
Sechenov First Moscow State Medical University (Sechenov University), Moscow

2 Department of Clinical Pharmacology and Propaedeutics of Internal Diseases, Faculty of General Medicine,
Sechenov First Moscow State Medical University (Sechenov University), Moscow

3 Center of Pharmaceutical Analytics Ltd., Moscow

Correspondence should be addressed: Maria V. Lukina
Bolshaya Pirogovskaya, 2 bl.4, Moscow, 119435; ur.xednay@0102kul-iram

About paper

Acknowledgements: the authors wish to thank Oleg V. Babenko, Chief Physician of the University Clinical Hospital No.1 of Sechenov First Moscow State Medical University for providing an opportunity to carry out our research

Received: 2018-05-16 Accepted: 2018-08-25 Published online: 2018-10-11
|
  1. Rybak M, Lomaestro B, Rotschafer JC, Moellering R, Craig W, Billeter M, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health- System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases. Am J Health Syst Pharm. 2009 Jan 1; 66 (1): 82–98.
  2. Ye ZK, et al. Therapeutic drug monitoring of vancomycin: a guideline of the Division of Therapeutic Drug Monitoring. J Antimicrob Chemother. 2016 Nov 11; 71 (11): 3020–25.
  3. Bondareva I. B. Programmnoe obespechenie dlya analiza dannyh FK/FD issledovanij. Klinicheskaya farmakokinetika. 2005; 2 (3): 9–13.
  4. Brendel K, Dartois C, Comets E, et al. Are population pharmacokinetic and/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004. Clin Pharmacokinet. 2007; 46 (3): 221–34.
  5. Clinical Calculators [internet]. Available from: http://clincalc.com/ Vancomycin.
  6. Lake KD, Peterson CD. A simplified dosing method for initiating vancomycin therapy. Pharmacotherapy. 1985 Nov-Dec; 5 (6): 340–44.
  7. Al-Kofide H, Zaghloul I, Al-Naim L. Pharmacokinetics of vancomycin in adult cancer patients. J Oncol Pharm Pract. 2010 Dec 16; 16 (4): 245–250.
  8. Burton ME, Gentle DL, Vasko MR. Evaluation of a Bayesian method for predicting vancomycin dosing. DICP. 1989; 23 (4): 294–300.
  9. Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract. 2012; 120 (4): 179–84.
  10. Instrukciya po medicinskomu primeneniyu [internet]. Available from: http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid= 80390ff0-c656-4e1b-a33e-a30232cccf1d&t=.
  11. Hammett-Stabler CA, Johns T. Laboratory guidelines for monitoring of antimicrobial drugs. Clin Chem. 1998 May; 44 (5): 1129–40.
  12. Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2017 Available from: https://www.R-project.org.
  13. Bauer LA. Applied clinical pharmacokinetics. New York: McGraw- Hill, 2001.р. 26–49.
  14. Matzke GR, McGory RW, Halstenson CE, Keane WF. Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimicrob Agents Chemother. 1984 Apr;25(4):433–7.
  15. Patel N, Pai MP, Rodvold KA, Lomaestro В, Drusano GL, Lodise TP. Vancomycin: we can’t get there from here. Clin Infect Dis. 2011 Apr 15; 52 (8): 969–74.
  16. Bel КА, Bourguignon L, Marcos M, Ducher M, Goutelle S. Is trough concentration of vancomycin predictive of the area under the curve? A clinical study in elderly patients. Ther Drug Monit. 2017 Feb; 39 (1): 83–7.
  17. Moise-Broder PA, Forrest A, Birmingham MC, et al. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet. 2004; 43 (13): 925–42.
  18. Paglialunga S, Offman E, Ichhpurani N, Marbury TC, Morimoto BH. Update and trends on pharmacokinetic studies in patients with impaired renal function: practical insight into application of the FDA and EMA guidelines. Expert review of clinical pharmacology. 2017; 10 (3): 273–83.
  19. Prybylski JP. Vancomycin Trough Concentration as a Predictor of Clinical Outcomes in Patients with Staphylococcus aureus Bacteremia: A Meta-analysis of Observational Studies. Pharmacotherapy. 2015 Oct; 35 (10): 889–98.
  20. Murphy JE, Gillespie DE, Bateman CV. Predictability of vancomycin trough concentrations using seven approaches for estimating pharmacokinetic parameters. Am J Health Syst Pharm. 2006 Dec 1; 63 (23): 2365–70.
  21. del Mar Fernández de Gatta Garcia M, Revilla N, Calvo MV, Domínguez-Gil A, Sánchez Navarro A. Pharmacokinetic/ pharmacodynamic analysis of vancomycin in ICU patients. Intensive Care Med. 2007 Feb; 33 (2): 279-85.
  22. Neely MN, Youn G, Jones B, Jelliffe RW, Drusano GL, Rodvold KA, et al. Are vancomycin trough concentrations adequate for optimal dosing? Antimicrob Agents Chemother. 2014; 58 (1): 309–16.
  23. Pai MP, Neely M, Rodvold KA, Lodise TP. Innovative approaches to optimizing the delivery of vancomycin in individual patients. Adv Drug Deliv Rev. 2014 Nov 20;77:50–7.
  24. Purwonugroho TA, Chulavatnatol S, Preechagoon Y, Chindavijak B, Malathum K, Bunuparadah P. Population pharmacokinetics of vancomycin in Thai patients. The Scientific World Journal. 2012;2012:762649. DOI: 10.1100/2012/762649.
  25. Zalloum N, Saleh MI, Al Haj M, Balbisi M, Al-Ghazawi M. Population pharmacokinetics of vancomycin in Jordanian patients Tropical Journal of Pharmaceutical Research. 2018; 17 (2): 351–58.